Investigational Inhibitor of Active RAS Shows Clinical Promise
The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C...
Search/Filter
Loading...
New Investigational Targeted Therapy Shows Early Promise in Patients With Solid Tumors
Second-generation PRMT5 inhibitor targets synthetic lethality in several cancer types with MTAP loss BOSTON – AMG 193, a second-generation...
Folakemi T. Odedina, PhD, Recognized with 2023 AACR Distinguished Lectureship on the Science of Cancer Health Disparities
ORLANDO, Fla. – The American Association for Cancer Research (AACR) will award Folakemi T. Odedina, PhD, with the 2023...
NCI-sponsored Cancer Clinical Trials Have Become More Diverse Over Past Two Decades
ORLANDO, Fla. – Compared to the year 2000, a greater proportion of NCI-sponsored early-phase clinical trial participants in 2022...
Structural Racism May Play a Role in Increased Cancer Mortality Rates Among Racial Minorities
ORLANDO, Fla. – Structural racism was associated with increased county-level cancer mortality rates among minority populations compared with whites,...
Racial and Ethnic Minorities May Be Less Willing Than Others to Participate in Clinical Trials
Survey found that most people are open to participating, and motivation varied by racial and ethnic group ORLANDO, Fla....
Spanish-speaking Men in Sexual Minority Groups May Lack Knowledge About Cancers Linked to HPV
Most men in survey were never offered the HPV vaccine ORLANDO, Fla. – A study found multiple gaps in...
Racial/Ethnic Minority Patients May Be Less Likely Than White Patients to Receive Palliative Care During Breast Cancer Treatment
Palliative care use increased among all racial/ethnic groups from 2004 to 2020 ORLANDO, Fla. – Despite a steady increase...
Brain Metastases in Patients with Kidney Cancer May Have Immune-suppressive Tumor Microenvironments
Researchers applied single-nucleus RNA sequencing and spatial transcriptomics to identify potential therapeutic targets in brain metastases ORLANDO, Fla. –...
Olaparib Plus Ceralasertib May Benefit Pediatric Cancer Patients With DNA Repair-deficient Tumors
ORLANDO, Fla. – A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical...